ACIU — AC Immune SA Income Statement
0.000.00%
Last trade - 00:00- $291.19m
- $137.05m
- CH₣27.31m
- 39
- 14
- 47
- 24
Annual income statement for AC Immune SA, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.4 | 0 | 3.94 | 14.8 | 27.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 76.7 | 79 | 74.8 | 68.4 | 79.7 |
| Operating Profit | -61.3 | -79 | -70.8 | -53.6 | -52.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -61.9 | -73 | -70.7 | -54.2 | -50.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -61.9 | -73 | -70.8 | -54.2 | -50.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -61.9 | -73 | -70.8 | -54.2 | -50.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -61.9 | -73 | -70.8 | -54.2 | -50.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.861 | -0.974 | -0.847 | -0.64 | -0.511 |